Name: MDV3100 (Enzalutamide)
Price: 236.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    MDV3100, known as Enzalutamide, is a second-generation androgen receptor (AR) signaling inhibitor. It has been demonstrated impressive affinity to the AR compared to the first-generation AR inhibitors. It is able to inhibit binding of androgens to the AR, AR nuclear translocation, and the association of the AR with DNA. The AR is a 919-amino acid member of the steroid receptor transcription factor superfamily with different domains including an N-terminal regulation domain, a central DNA binding domain, and a C-terminal domain, which includes the ligand-binding domain incorporated within its protein structure. MDV3100 was identified by the Sawyers/Jung laboratories by using the nonsteroidal agonist. Testing was showing that it induced apoptosis in VCaP cells, an AR gene amplified human prostate cancer line, while bicalutamide was ineffective.
- Properties
  - Categories
    
    Androgen receptor antagonist
    
    Alternative Name
    
    Enzalutamide, MDV3100, MDV-3100, MDV 3100; 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
    
    CAS Number
    
    915087-33-1
    
    Molecular Formula
    
    C21H16F4N4O2S
    
    Molecular Weight
    
    464.4
    
    Appearance
    
    A solid
    
    Purity
    
    99.12%
    
    Solubility
    
    ≥23.22 mg/mL in DMSO; insoluble in H2O; ≥9.44 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
    
    * For Research Use Only
- Reference
  - 1. Nair Lopes, Mariana Brütt Pacheco, et al. "Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer." Biomedicines. 2021 Aug 7;9(8):976. PMID:34440180
    2. Nicolas Malaquin, Arthur Vancayseele, et al. "DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity." Cells 2020, 9(7), 1593;1 July 2020. PMID:32630281
    3. Alajati A, D'Ambrosio M, et al. "CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo." J Clin Invest. 2020;130(5):2435-2450. PMID:32250342
    4. Khurana N, Chandra PK, et al. "Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells." Antioxidants (Basel). 2020;9(1):E68. PMID:31940946
    5. PAIGE M. GLUMAC. "Targeting CD133 In Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer." UNIVERSITY OF MINNESOTA. 2019.
    6. Hintz HM, Cowan AE, et al. "Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma." Bioconjug Chem. 2019 May 15;30(5):1466-1476. PMID:30966746
    7. Zhang Y, Zheng D, et al. "Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers." Nat Commun. 2018 Oct 4;9(1):4080. PMID:30287808
    8. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600. PMID:30190514
    9. Calcinotto A, Spataro C, et al. "IL-23 secreted by myeloid cells drives castration-resistant prostate cancer." Nature.2018 Jul;559(7714):363-369. PMID:29950727
    10. Khurana N, Kim H, et al. "Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer." Oncol Rep. 2017 Aug 30. PMID:28901514
    11. Audet-Walsh É, Dufour CR, et al. "Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer." Genes Dev. 2017 Jul 19. PMID:28724614
    12. Bao D, Cheng C, et al. "Regulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression."Oncotarget. 2017 Apr 4;8(14):23142-23154. PMID:28423563
    13. Sun J, Wang D, et al. "Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo." Front Neurosci. 2017 Mar 7;11:116. PMID:28326012
    14. Audet-Walsh É, Yee T, et al. "Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer." Cancer Res. 2017 Jan 15;77(2):378-389. PMID:27821488
    15. Khurana N, Talwar S, et al. "Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells." Int J Oncol. 2016 Oct;49(4):1609-19. PMID:27499349
    16. Wang L, Wang J, et al. "Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer." EBioMedicine. 2016 May;7:50-61. PMID:27322458
    17. Bogner J, Zolghadr K, et al. "The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators." J Steroid Biochem Mol Biol. 2016 May 9. PMID:27174722